Using Bayesian hierarchical modeling for performance evaluation of clinical trial accrual for a cancer center
-
Published:2024-04
Issue:
Volume:38
Page:101281
-
ISSN:2451-8654
-
Container-title:Contemporary Clinical Trials Communications
-
language:en
-
Short-container-title:Contemporary Clinical Trials Communications
Author:
Shi XiaosongORCID,
Mudaranthakam Dinesh PalORCID,
Wick Jo A.ORCID,
Streeter DavidORCID,
Thompson Jeffrey A.,
Streeter Natalie R.ORCID,
Lin Tara L.,
Hines Joseph,
Mayo Matthew S.,
Gajewski Byron J.ORCID
Reference17 articles.
1. Guerra CE, Fleury ME, Byatt LP, et al. Strategies to Advance Equity in Cancer Clinical Trials. American Society of Clinical Oncology Educational Book; 127–137..
2. Unger JM, Hershman DL, Till C, et al. “when offered to participate”: a systematic review and meta-analysis of patient agreement to participate in cancer clinical trials. JNCI: Journal of the National Cancer Institute; 113: 244–257..
3. Denicoff AM, McCaskill-Stevens W, Grubbs SS, et al. The national cancer institute–American society of clinical Oncology cancer trial accrual symposium: summary and recommendations. Journal of Oncology Practice; 9: 267–276..
4. Mudaranthakam DP, Phadnis MA, Krebill R, et al. Improving the efficiency of clinical trials by standardizing processes for investigator initiated trials. Contemporary Clinical Trials Communications; 18: 100579..
5. Mudaranthakam DP, Thompson J, Hu J, et al. A curated cancer clinical outcomes database (C3OD) for accelerating patient recruitment in cancer clinical trials. JAMIA Open; 1: 166–171..